A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.
Also called NCT01098539
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 507 participants
- Sponsor
- Registry
-
NCT01098539
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Brazil, Colombia, Germany, India, Israel, Peru, Philippines, Russia, South Africa, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01098539. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-05-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Biological)
- albiglutide
- Intervention (Drug)
- sitagliptin
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01098539- Content hash
62cb6aa6d693b3808703130f92cd4c75c42c8a1756c703331c0e48453408ab12